UBS and Citi Go Bullish on Gilead Sciences (GILD) [Yahoo! Finance]
Gilead Sciences, Inc. (GILD)
Last gilead sciences, inc. earnings: 4/30 04:01 pm
Check Earnings Report
US:NASDAQ Investor Relations:
investors.gilead.com
Company Research
Source: Yahoo! Finance
On January 7, 2026, reports highlighted that analysts are increasingly confident in Gilead Sciences, Inc. (NASDAQ:GILD)'s short- and medium-term outlook, driven by optimism around the company's HIV franchise. On that day, UBS analyst Michael Yee upgraded the stock from ‘Neutral' to ‘Buy' and raised the firm's price target from $112 to $145, according to The Fly. The analyst expects strong HIV pre-exposure prophylaxis sales from Yeztugo, which could potentially boost both revenue and earnings. At the same time, the analyst expects visibility into the company's outer-year growth trajectory to improve. Furthermore, Yee highlighted the company's focus on prevention-based HIV therapies, which reflects a strategic evolution of the company's core antiviral business toward more durable, growth-oriented demand drivers. This positive update was accompanied by another on the same day, with Citi's analyst Geoff Meacham raising the firm's target from $135 to $140 and maintaining a ‘Buy' rating.
Show less
Read more
Impact Snapshot
Event Time:
GILD
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
GILD alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
GILD alerts
High impacting Gilead Sciences, Inc. news events
Weekly update
A roundup of the hottest topics
GILD
News
- Gilead Sciences: From All-Time Highs To Higher Highs [Seeking Alpha]Seeking Alpha
- The Bull Case For Gilead Sciences (GILD) Could Change Following New OncoNano Drug-Delivery Collaboration [Yahoo! Finance]Yahoo! Finance
- Is Gilead Sciences (GILD) Pricing Reflecting Recent 38.5% One Year Share Return? [Yahoo! Finance]Yahoo! Finance
- Gilead price target raised to $154 from $144 at BofA [Yahoo! Finance]Yahoo! Finance
- J&J cuts MFN deal with the Trump administration, bolsters US onshoring efforts [Yahoo! Finance]Yahoo! Finance
GILD
Earnings
- 10/30/25 - Beat
GILD
Sec Filings
- 1/5/26 - Form 4
- 12/30/25 - Form 4
- 12/29/25 - Form 144
- GILD's page on the SEC website